| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | CEP-701 | FIMM | pan-cancer | AAC | 0.029 | 0.8 |
| mRNA | CR-1-31B | CTRPv2 | pan-cancer | AAC | 0.0075 | 0.8 |
| mRNA | NVP-BEZ235 | CTRPv2 | pan-cancer | AAC | 0.0097 | 0.8 |
| mRNA | GW 441756 | GDSC1000 | pan-cancer | AAC | -0.008 | 0.8 |
| mRNA | Crizotinib | FIMM | pan-cancer | AAC | -0.04 | 0.8 |
| mRNA | BYL-719 | CTRPv2 | pan-cancer | AAC | 0.0097 | 0.8 |
| mRNA | tivantinib | CTRPv2 | pan-cancer | AAC | 0.01 | 0.8 |
| mRNA | Doxorubicin | GDSC1000 | pan-cancer | AAC | 0.0078 | 0.8 |
| mRNA | BMS-754807 | GDSC1000 | pan-cancer | AAC | -0.0073 | 0.8 |
| mRNA | BRD-K33199242 | CTRPv2 | pan-cancer | AAC | 0.008 | 0.8 |